Acetylcarnitine: Difference between revisions
proper capitalisation and formatting |
→Health claims: peyronie's dissease |
||
| Line 79: | Line 79: | ||
|url= |
|url= |
||
}}</ref> Research into the compound's safety and efficacy in humans is required. |
}}</ref> Research into the compound's safety and efficacy in humans is required. |
||
ALC has been shown to be more effective than [[tamoxifen]] in improving the curvature and reducing the pain and plaque sizes for men who sought treatment for their [[Peyronie's disease]] early and having low curvature deformities. <ref>{{cite|url=http://books.google.com/books?hl=en&lr=&id=nNc_SBEnyd0C&oi=fnd&pg=PA69&dq=Acetyl+L-Carnitine+improves+libido&ots=6rlblde3Q0&sig=sIx9RdOcG6x76uTPGjRN-HYJtSo|title=Peyronies Disease: A Guide to Clinical Management|editor=Laurence A. Levine M.D. FACS|publisher=Humana Press|chapter=Oral Therapy for Peyroni's Disease|author=Claudio Teloken, Tulio Graziottin & Patrick E. Teloken|accessdate=06-26-2009}}</ref> |
|||
==References== |
==References== |
||
Revision as of 05:21, 29 June 2009
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.130.594 |
| Chemical and physical data | |
| Formula | C9H17NO4 |
| Molar mass | 203.236 g·mol−1 |
Acetyl-L-carnitine or ALCAR, is an acetylated form of L-carnitine. ALCAR has been claimed to be superior to normal L-carnitine in terms of bioavailability. However, at least one study has suggested that the acetylated form may have a lower oral bioavailability.[1]
Chemical derivation
Acetyl-L-carnitine is an acetylated derivative of L-carnitine. L-Carnitine is derived from the amino acids lysine and methionine.
Health claims
ALCAR supplementation has been shown to be neuroprotective in instances of cerebral ischemia in rats[2] and may be useful in treating peripheral nerve injury.[3] It may have some neuroprotective benefit in the treatment of Parkinson's disease, but further research is required.[4] Research into the compound's safety and efficacy in humans is required. ALC has been shown to be more effective than tamoxifen in improving the curvature and reducing the pain and plaque sizes for men who sought treatment for their Peyronie's disease early and having low curvature deformities. [5]
References
- ^ Eder, K. (2005). "Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds". Int J Vitam Nutr Res. 75 (1): 3–9. doi:10.1024/0300-9831.75.1.3. Retrieved 2007-03-13.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Al-Majed AA, Sayed-Ahmed MM, Al-Omar FA, Al-Yahya AA, Aleisa AM, Al-Shabanah OA (2006). "Carnitine esters prevent oxidative stress damage and energy depletion following transient forebrain ischaemia in the rat hippocampus". Clin. Exp. Pharmacol. Physiol. 33 (8): 725–33. doi:10.1111/j.1440-1681.2006.04425.x. PMID 16895547.
{{cite journal}}: Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link) - ^ Wilson AD, Hart A, Brännström T, Wiberg M, Terenghi G (2007). "Delayed acetyl-L-carnitine administration and its effect on sensory neuronal rescue after peripheral nerve injury". J Plast Reconstr Aesthet Surg. 60 (2): 114–8. doi:10.1016/j.bjps.2006.04.017. PMID 17223507.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Beal MF (2003). "Bioenergetic approaches for neuroprotection in Parkinson's disease". Ann. Neurol. 53 Suppl 3: S39–47, discussion S47–8. doi:10.1002/ana.10479. PMID 12666097.
- ^ Claudio Teloken, Tulio Graziottin & Patrick E. Teloken, "Oral Therapy for Peyroni's Disease", in Laurence A. Levine M.D. FACS (ed.), Peyronies Disease: A Guide to Clinical Management, Humana Press, retrieved 06-26-2009
{{citation}}: Check date values in:|accessdate=(help)
Other reviews
- Jane Higdon, "L-Carnitine", Micronutrient Information Center, Linus Pauling Institute, Oregon State University
- "Carnitine (L-carnitine)", University of Maryland Medical Center